Experimental and clinical oncology

Our overall goal is to gain insight into the complex molecular mechanisms underlying tumour evolution, and to identify novel prognostic and/or predictive markers and treatment targets. In addition, the consequences of the disease and treatment for the physical, mental and social dimensions of patients’ wellbeing are investigated. 

The research programme includes experimental projects that are performed in the laboratory. Using modern molecular and cellular methods, we study patient derived tumour cells and relevant models for the tumour in vitro and in vivo, to identify essential pathways that may cause cancer or that will affect disease progression. We also want to find novel biomarkers that can be used for improved diagnostics and prognostication, or that may function as targets for new treatment strategies.

Our clinical research programme includes thorough evaluation of the effect of different treatment strategies, to find ways to determine which therapy is most efficient for the individual patients. New treatment modalities, including immunotherapy, are also studied. With the aim to improve immediate patient care, we also study the effects of interventions to diminish treatment toxicity and improve health related quality of life.
 

Research groups

• Panagiotis Baliakas – Molecular genetics of hematological malignancies
   
• Gunilla Enblad – Tumour biology and clinical parameters for diffuse large B-cell lymphoma
   
• Bengt Glimelius – Colorectal cancer
   
• Linda Holmfeldt – Molecular characterization of acute leukemia
   
• The control of survival and apoptosis in human multiple myeloma – Helena Jernberg Wiklund
• Birgitta Johansson – Caring sciences in oncology care
   
• Magnus Lindskog – Prognostic and predictive factor in advance cancer in the airways or kidneys
   
• Peter Nygren – Individualised, more efficient cancer therapy
   
• Tobias Sjöblom – Molecular cancer genetics
   
• Gustav Ullenhag – Translational immunotherapy